CORT (Corcept Therapeutics) Common Stock: $0.1 Mil (As of Mar. 2026)


CORT Corcept Therapeutics Inc CORT
82 GF Score
Price $87.32
GF Value $61.67
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Common Stock?

Corcept Therapeutics CORT +3.03% 82 Common Stock is $0.1 Mil as of Mar. 2026. GuruFocus rates CORT with a GF Score™ of 82/100 and a GF Value™ of $61.67 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Corcept Therapeutics's quarterly common stock increased from Sep. 2025 ($0.1 Mil) to Dec. 2025 ($0.1 Mil) and increased from Dec. 2025 ($0.1 Mil) to Mar. 2026 ($0.1 Mil).

Corcept Therapeutics's annual common stock increased from Dec. 2023 ($0.1 Mil) to Dec. 2024 ($0.1 Mil) and increased from Dec. 2024 ($0.1 Mil) to Dec. 2025 ($0.1 Mil).

Corcept Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Common Stock Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.13 0.13 0.14 0.14

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.14 0.14 0.14
CORT
82GF Score
Corcept Therapeutics Inc CORT
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.1 Mil mean?
Corcept Therapeutics (CORT) has a Common Stock of $0.1 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Common Stock too high?
Corcept Therapeutics' current Common Stock is $0.1 Mil. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Common Stock compare to PCVX and IBRX?
Corcept Therapeutics' Common Stock of $0.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Common Stock is $0.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.67, compared to a current price of $87.32 — trading 41.6% above its estimated fair value. The current Common Stock is $0.1 Mil. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Common Stock is $0.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (CORT) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of $87.32 is trading 41.6% above its estimated GF Value™ of $61.67. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for CORT:

  • Common Stock: $0.1 Mil
  • GF Value™: $61.67 vs. price of $87.32 (41.6% above fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score

Get the complete analysis for CORT

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$87.32
Price
$61.67
GF Value